Quironsalud Madrid
| Turchia | Austria | Spagna | |
| Chemioterapia per il cancro alla prostata | da $1,000 | - | da $5,131 |
Il medico è un oncologo medico distinto con oltre 30 anni di esperienza, specializzato nel trattamento non chirurgico dei tumori genitourinari, inclusi i tumori della prostata, del rene e della vescica, nonché sarcomi e tumori di origine sconosciuta. Attualmente, il medico guida l'Unità Tumori Genitourinari, del Sistema Nervoso Centrale, Sarcomi e Tumori di Origine Sconosciuta presso l'Ospedale Universitario Vall d'Hebron di Barcellona ed è affiliato al Centro Medico Teknon.<\/p>
Con un dottorato in Medicina e Chirurgia, il medico ha guidato numerosi studi clinici multicentrici nazionali ed è autore di oltre 120 articoli sottoposti a revisione paritaria. Il medico è riconosciuto come uno dei principali esperti in oncologia genitourinaria in Spagna.<\/p>
Il medico è un oncologo pediatrico con 37 anni di esperienza, specializzato nel trattamento dei disturbi del sangue e nell'esecuzione di procedure come i trapianti di midollo osseo e la terapia ablativa. Attualmente, il medico è Capo dell'Emato-Oncologia Pediatrica presso l'Ospedale Universitario Quironsalud Madrid.<\/p>
Con un prolifico curriculum accademico, il medico ha curato 14 libri, contribuito a 75 capitoli di libri e presentato a oltre 200 conferenze. Il medico è membro di diverse associazioni professionali, tra cui l'Associazione Spagnola di Ematologia Pediatrica e l'Associazione Spagnola di Oncologia Pediatrica.<\/p>
Il medico tratta un'ampia gamma di condizioni, tra cui leucemia, linfoma, mieloma multiplo e vari disturbi ematologici e autoimmuni.<\/p>
Medical Director of the University of Navarra Clinic
Prof. of hematology and hemotherapy
Dr. Begona Mellado Gonzalez is a senior oncologist specializing in urological cancers at Hospital HM Nou Delfos. She has published over 140 scientific articles in international journals. Dr. Mellado Gonzalez completed a post-doctoral stay at Memorial Sloan-Kettering Cancer Center in New York. She serves as a leading researcher for prostate cancer at the IDIBAPS institute.
Chemotherapy for prostate cancer in Spain is primarily reserved for advanced, metastatic, or life-threatening stages. Oncologists typically prescribe it when cancer progresses despite hormone therapy (mCRPC) or for high-volume metastatic cases. Specialists often integrate chemotherapy with androgen deprivation therapy to manage cells spread beyond the prostate.
Bookimed Expert Insight: Spanish centers like Clinica Universidad de Navarra differentiate care by combining ESMO-certified protocols with genomic profiling. Our data shows high-volume centers often prefer this precision approach to determine if chemotherapy or Lu-177 PSMA radioligand therapy is the most effective next step for stage 4 patients.
Patient Consensus: Patients emphasize that chemotherapy is never the first option for early-stage diagnosis in Spain. Many advise requesting early evaluations for metastatic potential if initial hormone treatments begin to show declining effectiveness.
Standard chemotherapy for prostate cancer in Spain focuses on taxanes for advanced or metastatic stages. Docetaxel serves as the primary first-line treatment, while Cabazitaxel is the established second-line option. These therapies are administered by oncology specialists at Joint Commission International (JCI)-accredited facilities like Centro Médico Teknon.
Bookimed Expert Insight: Spain offers high-level oncology care with significant cost benefits. Patients can access JCI-accredited centers like Clinica Universidad de Navarra for $2,500 to $4,500. This represents a saving of _price_percent_discount_% compared to US averages of _price_compare_US_average_. Leading hospitals like Quironsalud Madrid even provide access to experimental clinical trials for complex cases.
Patient Consensus: Many patients find that Spanish protocols strictly reserve chemotherapy for metastatic disease rather than early diagnosis. Expect to focus on hormone therapy first before transitioning to taxane-based drugs.
Modern imaging in Spain provides detailed maps for prostate cancer staging and chemotherapy baseline establishment. Advanced tools like PSMA PET/CT scans and 3T MRI identify metabolic activity or structural lesions. These diagnostic techniques allow oncologists to track molecular regression and confirm treatment success effectively.
Bookimed Expert Insight: Spanish oncology centers like Clinica Universidad de Navarra use AI-assisted diagnostics alongside 3T MRI to personalize chemotherapy. Centers serving over 140,000 patients annually often prioritize PSMA PET/CT for high-risk cases. This high patient volume ensures radiologists have exceptional expertise in reading complex molecular scans.
Patient Consensus: Patients emphasize requesting a specific PSMA PET scan rather than a generic PET for higher sensitivity. Many recommend a multi-disciplinary tumor board review to interpret these advanced imaging results accurately.
International patients can participate in oncology clinical trials in Spain, a global leader in early-phase cancer research. Facilities like Quironsalud Madrid offer trials where treatments are provided free of charge if specific medical requirements and diagnostic criteria are met.
Bookimed Expert Insight: Spanish oncology research has shifted significantly toward radioligand therapy. While many seek chemotherapy trials, data shows high demand for Lu-177 PSMA (Pluvicto) in Madrid and Barcelona. These advanced radiation treatments are often more accessible through research protocols than standard drug-based chemotherapy trials.
Patient Consensus: Many patients find that focusing on immunotherapy or radioligand trials provides more options than traditional chemotherapy. It is essential to consult your local oncologist first to explore compassionate use programs before traveling.